pharmact 产品代理

SARS-CoV-2 Antibody testing

Screening for metabolic diseases on early stages

IN-VITRO DIAGNOSTIC

R & D

Pharmact BioScience GmbH is developing technologies and immunoassays to address today’s major medical challenges such as myocardial infarction, diabetes mellitus and severe liver diseases as well as various compounds for therapeutic purposes. Our core values are innovation, excellence, integrity and safety.

IVD – POINT-of-CARE-TEST

First, we have developed and launched three rapid tests (IVD) which will support our project on arteriosclerosis therapy. These point-of-care tests are the initial results of Pharmact AG’s multinational team.

Our tests for diagnosing a developing type 2 diabetes or liver diseases at an early stage enable rapid diagnostics of the two organs pancreas and liver.